Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +1.69% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 38 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M 100.0% | $65.2M 100.0% | $107.4M 100.0% | $96.7M 100.0% | $65.6M 100.0% | $27.6M 100.0% | $7.3M 100.0% | $3.7M 100.0% | $3.2M 100.0% | $2.6M 100.0% |
| Cost of Revenue | $20.6M 31.0% | $16.1M 24.7% | $40.8M 38.0% | $44.4M 45.9% | $36.4M 55.5% | $8.3M 30.0% | $2.2M 30.1% | $2.1M 56.0% | $1.4M 44.0% | $957K 37.4% |
| Gross Profit | $45.8M 69.0% | $49.1M 75.3% | $66.6M 62.0% | $52.3M 54.1% | $29.2M 44.5% | $19.4M 70.0% | — | — | — | — |
| Research & Development | $1.3M 2.0% | $2.8M 4.2% | $4.1M 3.8% | $12.7M 13.1% | $5.6M 8.6% | $1.7M 6.2% | $589K 8.0% | $168K 4.6% | $960K 29.8% | $6.1M 239.1% |
| Selling, General & Admin | $17.4M 26.2% | $20.0M 30.6% | $28.6M 26.7% | $31.2M 32.2% | $25.5M 38.9% | $34.8M 125.9% | $18.9M 258.0% | $17.7M 484.5% | $17.4M 541.4% | $8.5M 332.4% |
| Total Operating Expenses | $53.7M 80.8% | $50.6M 77.7% | $83.7M 77.9% | $162.2M 167.8% | $88.1M 134.2% | $40.5M 146.5% | $24.2M 330.1% | $23.4M 638.2% | $23.3M 724.7% | $24.3M 947.0% |
| Operating Income | -$7.8M -11.8% | -$1.6M -2.4% | -$17.1M -15.9% | -$109.9M -113.7% | -$58.9M -89.7% | -$21.1M -76.5% | -$16.8M -230.1% | -$19.7M -538.2% | -$20.1M -624.7% | -$21.7M -847.0% |
| Interest Expense | $3.7M 5.6% | $5.1M 7.8% | $5.0M 4.6% | $900K 0.9% | — | $2.6M 9.4% | $536K 7.3% | $749K 20.5% | $2.5M 78.7% | $5.5M 214.3% |
| Other Income (Expense), net | -$512K -0.8% | $870K 1.3% | $14K 0.0% | $1.0M 1.1% | $840K 1.3% | $7.5M 27.2% | -$10.3M -140.5% | $9.5M 259.9% | -$2.4M -74.0% | -$6.5M -252.7% |
| Pretax Income | -$13.7M -20.7% | -$10.4M -15.9% | -$17.1M -15.9% | -$108.9M -112.6% | -$58.0M -88.4% | -$13.6M -49.3% | — | — | — | -$28.2M -1099.7% |
| Income Tax Expense | $437K 0.7% | $2.1M 3.3% | $0 0.0% | -$110K -0.1% | $259K 0.4% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | -$13.6M -20.4% | -$15.8M -24.3% | -$17.1M -15.9% | -$108.8M -112.5% | -$58.3M -88.8% | -$13.6M -49.3% | -$27.1M -370.6% | -$10.2M -278.3% | -$22.5M -698.7% | -$28.2M -1099.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-3.48 | — | — | — | — | — |
| EPS (Diluted) | — | — | $-5.11 | $-74.01 | $-3.48 | — | — | — | — | — |
| Weighted Avg Shares (Basic) | 6.3M | 5.5M | 3.3M | 1.5M | 16.7M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | — | — | 3.3M | 1.5M | 16.7M | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$2M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -43%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $31M covers all $12M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-31 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~29.0% on $13M of debt.
Cash of $31M fully covers short-term debt of $2M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 12-yr range · 21th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 12-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 213.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 56.0 | 30.1 | 30.0 | 55.5 | 45.9 | 38.0 | 24.7 | 31.0 |
| Gross Profit | — | — | 70.0 | 44.5 | 54.1 | 62.0 | 75.3 | 69.0 |
| R&D | 4.6 | 8.0 | 6.2 | 8.6 | 13.1 | 3.8 | 4.2 | 2.0 |
| SG&A | 484.5 | 258.0 | 125.9 | 38.9 | 32.2 | 26.7 | 30.6 | 26.2 |
| Operating Income | -538.2 | -230.1 | -76.5 | -89.7 | -113.7 | -15.9 | -2.4 | -11.8 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.4 | -0.1 | 0.0 | 3.3 | 0.7 |
| Net Income | -278.3 | -370.6 | -49.3 | -88.8 | -112.5 | -15.9 | -24.3 | -20.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AYTU: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| AYTU | $18M | — | — | 0.3× | 1.8% | 69.0% | -20.4% | -71.5% | -42.8% | -1.7× | 38 |
Peers = companies sharing AYTU's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.